Disgruntled Novartis questions the worth of Indian patents
This article was originally published in Scrip
Executive Summary
Stung by the rising tide of voices supporting the recent Indian Supreme Court verdict rejecting a patent for Glivec ((imatinib mesylate), Novartis sought to dispel certain ‘myths’ around the issue , while emphasizing that improving access to healthcare requires much more than products and affordability.